By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel agrees that while Schedule III rescheduling provides immediate tax relief to cannabis operators, it falls short of full legalization and comes with significant risks. The key concern is that increased liquidity from tax relief could lead to aggressive expansion and overproduction, potentially offsetting the margin gains and driving down wholesale prices before interstate commerce opens.
Risk: Cannibalization risk: aggressive expansion in saturated markets leading to a supply glut and price war.
Opportunity: Immediate tax relief for cannabis operators, potentially improving margins by 15-25%.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Marijuana has had a history of highs and lows in the U.S. over the past century — legally, politically and culturally — teetering between vilification and acceptance. Since 1996, 40 states and the District of Columbia have legalized either medical or recreational adult-use marijuana. Yet cannabis, the leafy plant from which marijuana is derived, is still a federally illegal Schedule I drug as defined by the 1970 Controlled Substances Act.
With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an important issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
Marijuana may not be as critical to voters as the economy, immigration, the war with Iran and the build-out of AI data centers. But it will likely be on the minds of Democrats and Republicans over the next few months.
"It's certainly a very popular issue among voters," said Morgan Fox, political director for NORML, a non-profit group that advocates for cannabis legalization. "It's possible that it could become a more important issue as we get closer to the midterms, particularly if Republicans are worried about losing one or both chambers."
President Donald Trump shined a political grow light on the issue last December when he urged the Justice Department to expedite the reclassification of marijuana from Schedule I to Schedule III, a category that includes Tylenol with codeine, ketamine and testosterone.
The timing of Trump's announcement — coupled with his administration's recent order to fast-track approval of psychedelic drugs, as well the president's slumping approval rating — could be seen as a tactic to boost Republican voters who support loosening drug restrictions. It also steals thunder from Democrats, who had failed to reschedule cannabis during Biden's tenure.
Trump's switch came to fruition, at least partially, in April. Acting Attorney General Todd Blanche signed an order to reschedule state-licensed medical marijuana to Schedule III, thereby easing research restraints and federal tax burdens on companies operating in the $30-billion legal cannabis industry. In a probable nod to voters, outgoing White House press secretary Karoline Leavitt said that rescheduling is "overwhelmingly popular with the vast majority of Americans."
Sixty-four percent of U.S. adults think the use of marijuana should be legal, according to a November Gallup poll.
But that popularity may not translate directly into votes, according to Kevin Sabet, CEO of Smart Approaches to Marijuana, a non-profit that opposes marijuana legalization and commercialization. He believes that cannabis reform will be a low-priority issue come November. "It's traditionally let down the politicians who thought they were going to be scoring some cheap votes," he said, "most recently, the president."
The Gallup data shows public support has declined from 70% in 2023, a trend that can be interpreted as politically motivated. Support for legalization among Republicans has fallen 13 points over the past year, to 40% from 53% — despite Trump's warming relationship with the industry — while it's been consistent among Democrats (85%) and independents (66%) in recent years.
At the federal level, "cannabis will still be illegal," Fox said of the rescheduling efforts. "The most concrete benefit of moving to Schedule III is 280E tax relief for cannabis businesses," he said, referring to the IRS code that prohibits legal cannabis companies from deducting otherwise established business expenses, such as payroll, rent and utilities, from gross income.
"280E has always been one of those things that you just have to operate around," said Matthew Merlander, president of Sun Theory, a vertically integrated company that cultivates cannabis and operates dispensaries and markets branded edibles. "We know that if [it] does go away, that inherently makes the industry more profitable."
Sabet concedes that the industry would benefit from the removal of 280E. "I just don't think it's a good thing," he said. "The last thing pot companies need are tax breaks."
In fact, the prospect of rescheduling stoked Trump supporters in the industry who have lobbied the administration for federal and state reforms to onerous cannabis regulations. Most prominent among them is Kim Rivers, CEO of Trulieve, one of the largest U.S. cannabis companies, who donated $750,000 to the president's inauguration last year and attended a private $1 million-per-plate fundraiser at Trump's New Jersey golf club, where she urged the president to follow through on marijuana rescheduling and expand medical-cannabis research, according to the Wall Street Journal.
To date, Trulieve and other industry leaders, including Curaleaf, Green Thumb Industries and Verano Holdings, have contributed roughly $11.5 million into the Trump-aligned super PAC America First Agriculture Action Inc. ahead of the midterms, according to filings with the Federal Election Commission.
Nonetheless, many Republican lawmakers oppose cannabis reforms. More than 20 GOP senators and several House members signed letters urging the White House to halt reclassification. In August 2025, Rep. Paul Gosar (R-AZ) wrote, "Marijuana rescheduling will … not be the boon to the Republicans' midterm chances like Big Weed claims. In fact, reclassifying marijuana as a Schedule III drug would be a self-own for the Republican Party in 2026."
Across the aisle, Congressional Democrats tepidly endorsed the order, labelling it a partial solution that fell short of full legalization, a policy that many in the party favor. Last month, 17 Senate Democrats, led by Cory Booker (NJ), Chuck Schumer (NY) and Ron Wyden (OR), reintroduced the Cannabis Administration and Opportunity Act, for the second time. If it passes, the legislation calls for completely removing cannabis from the Controlled Substances Act and ending its federal prohibition.
"Voters across the country have made it clear they want cannabis legalized, and Trump's half measures aren't fooling anyone," Sen. Wyden said in an email statement to CNBC. "Anything less than full descheduling at the federal level is an attempt to juice Trump's numbers ahead of November, because he knows his platform of driving up gas prices and giving tax breaks to billionaires is about to lose him the midterms. The best path forward is passing" the CAOA, he said.
Even so, in its most recent party platform, issued in 2024, Democrats stopped short of officially endorsing federal recreational legalization or complete descheduling of marijuana. The 2024 Republican Party platform did not take a clear position on cannabis legalization or rescheduling.
Historically, marijuana is no stranger to controversy. The Marihuana Tax Act of 1937 effectively criminalized what until then had been legal cannabis. Two years later, "Reefer Madness" terrified movie-going parents. That set the tone decades later for President Richard Nixon to sign the Controlled Substance Act, condemning marijuana as a Schedule I drug alongside heroin and LSD.
Americans kept lighting up, though, even after draconian federal and state anti-drug laws were enacted during the 1990s. Millions of people were arrested for possessing and selling marijuana and hundreds of thousands were incarcerated, some receiving life sentences. In 1996, 75% of the public opposed legalization.
That same year, however, California breached the War on Drugs barricades, becoming the first state to legalize medical marijuana. Fifteen states have since followed suit. Then in 2012, Colorado and Washington became the first states to legalize recreational adult-use cannabis. To date, only Idaho and Kansas ban marijuana outright.
Idaho voters will have a chance in November to decide whether or not to keep it that way. An amendment on the ballot would grant the state legislature exclusive authority to prohibit citizen-initiated ballot measures on marijuana, narcotics and psychoactive substances. An initiative to legalize only medical cannabis failed to make the ballot, despite the fact that nearly three-quarters of surveyed voters favored the measure.
Marijuana is not on the ballot in Kansas, though it may well come up in the race for governor. The Democratic candidate, Cindy Holscher, publicly endorsed recreational marijuana legalization during her primary campaign. Her GOP opponent, state senate president Ty Masterson, objects to legalization of recreational marijuana and has consistently blocked medical marijuana legislation from moving forward.
Similarly, in nearby Iowa, where medical marijuana has been legal since 2017, the gubernatorial candidates are on opposite sides of the legalization issue. The GOP's Zach Lahn has clearly stated that he would not support legalizing recreational marijuana, while Democrat Rob Sand said in April, "I'm announcing my plan to legalize, tax and regulate adult-use cannabis."
The electorate in Massachusetts is facing a more peculiar, and contentious, ballot measure. "An Act to Restore a Sensible Marijuana Policy" would retain the Bay State's medical marijuana program, overwhelmingly approved in 2012, while repealing its 2016 vote to legalize recreational marijuana sales and cultivation, which passed by a margin of 54% to 46%. This current initiative would mark the first time a voter-approved legalization measure was overturned.
"It's a total uphill battle, definitely David and Goliath," Sabet said. "The marijuana industry can't believe it qualified, but at the same time [is] mobilizing very strongly to get this to fail."
Sabet said that SAM was "one of the donors for that ballot initiative." The Massachusetts Office of Campaign and Political Finance filings show that the coalition behind the initiative received the entirety of its $1.5 million in fund-raising from SAM. There have been additional contributions to the coalition since then, which will be reported in September. A group opposing the measure, "Stop the Repeal," challenged the signature process, but the State Ballot Law Commission denied its petition.
Regardless, said Fox, "It's pretty clear that this is not something people actually want."
A University of New Hampshire poll released in February found that 63% of Massachusetts voters oppose the measure, including 41% of Republicans surveyed. NORML will be heavily involved in working against it. "We want to make sure that this thing goes down in flames," he said.
There's plenty of time between now and the November 3 elections for voters to weigh key issues. Whether rescheduling, legalizing or restricting marijuana rises in importance remains to be seen. "There is definitely an impetus among folks that are supportive of cannabis policy reform to put their marker down before the midterms," Fox said. The various state initiatives and races being considered, in his view, indicate "a recognition that this is a politically popular issue."
Four leading AI models discuss this article
"Schedule III delivers limited 280E relief but leaves federal prohibition and banking barriers intact, capping re-rating potential ahead of volatile midterms."
The article portrays cannabis reform as a bipartisan midterm wedge issue with Trump's Schedule III move delivering 280E tax relief to a $30B industry (Trulieve, Curaleaf, Green Thumb, Verano). Yet federal prohibition remains, public support has slipped from 70% to 64%, and Republican backing cratered 13pts to 40%. State ballot fights in Idaho, Kansas, Iowa, and especially Massachusetts' repeal effort show momentum is uneven. Missing context: rescheduling still blocks interstate commerce and banking normalization; 280E relief is modest compared with full descheduling. Industry donations ($11.5M to Trump PAC) look like hedging, not conviction.
If Republican opposition hardens post-midterms and the Massachusetts repeal succeeds, it could trigger a regulatory rollback wave that freezes capital flows into the sector far longer than the article admits.
"Schedule III rescheduling is a fiscal bridge for existing operators but remains a regulatory trap that prevents the industry from achieving true institutional legitimacy."
The market is mispricing the impact of Schedule III rescheduling. While the removal of 280E tax burdens provides a direct, immediate boost to cash flow for MSOs (Multi-State Operators) like Trulieve (TCNNF) and Green Thumb (GTBIF), the article ignores the existential risk of legal uncertainty. Even with rescheduling, these companies remain in violation of federal law, keeping them barred from major U.S. stock exchanges and institutional capital. The current political maneuvering is a tactical 'head-fake' to secure donor funding and voter turnout rather than a precursor to full legalization. I expect volatility to increase as the industry realizes that Schedule III is a regulatory ceiling, not a floor, for federal reform.
If 280E relief triggers a massive wave of institutional investment and uplisting to major exchanges, the current valuations for MSOs could see a 50-100% re-rating regardless of federal prohibition status.
"Schedule III relief is priced in for large-cap operators; the real catalyst—full descheduling—requires sustained political will that midterm results alone won't guarantee."
The article conflates political momentum with industry tailwinds. Schedule III reclassification is real and material—280E tax relief alone could improve cannabis operator margins by 15-25% depending on current tax burden—but it's NOT full legalization. The political theater masks a narrower win: Trulieve (TRUL), Curaleaf (CURLF), Green Thumb (GTII) get tax relief, but remain trapped in a patchwork of state regulations with no interstate commerce. The $11.5M super PAC spend signals industry confidence, yet Republican defection (Gosar, 20+ GOP senators) and Democratic demands for full descheduling suggest this stalls post-midterms. Voter support (64%) doesn't translate to legislative action—it never has. The Massachusetts repeal attempt is the real tell: even legalized states face backlash.
Schedule III reclassification is already law as of April 2025 (per the article)—the political battle is won for operators regardless of midterm outcomes. If Republicans hold chambers, full descheduling becomes plausible within 24 months, which would unlock interstate M&A, banking access, and 10x+ upside for consolidated players.
"Policy momentum for cannabis reform is unlikely to translate into near-term earnings upside unless there is concrete federal action that improves margins (e.g., descheduling or robust 280E relief), not just ballot talk."
News frames cannabis reform as a political tailwind, but the real driver for equities is policy timing and earnings quality, not ballot talk. Rescheduling to Schedule III would relieve 280E tax drag and ease research constraints, but the effect is ambiguous until we see durable federal action; state ballots like Massachusetts' repeal proposal show reform is far from a monoculture win. Public support remains high but not a reliable predictor of votes; the GOP's mixed stance suggests policy risk remains; even full descheduling would take years to translate into bank access, M&A, and capex cycles. Investors should price in policy uncertainty and shifting earnings before evaluating multiple expansion.
Against my stance: federal descheduling or meaningful tax relief could materialize sooner than the article suggests, unlocking margin gains and attracting institutional buyers; if that happens, the stock rally could be swift and more durable than most expect.
"Premature legalization of Schedule III in Claude's take ignores ongoing legal limbo and risks faster price erosion at state level."
Claude's claim that Schedule III is "already law as of April 2025" is factually wrong; the article only discusses a proposed move, not enacted law. This undercuts the bullish counterfactual. The real risk nobody flagged is that even partial 280E relief could accelerate state-level overproduction, collapsing wholesale prices before interstate commerce ever opens.
"280E tax relief will likely trigger an overproduction cycle that compresses margins faster than tax savings can expand them."
Grok is right to call out Claude's factual error, but we are all missing the 'cannibalization' risk. If 280E relief hits, MSOs will use that liquidity to aggressively expand footprint, not just deleverage. This creates a supply glut in saturated markets like Illinois or Massachusetts, potentially offsetting margin gains from tax relief. Investors are betting on bottom-line expansion, but we are likely heading for a brutal price war that destroys the very cash flow the market is currently pricing in.
"280E relief funds a race-to-the-bottom in saturated markets, not margin expansion."
Gemini's cannibalization thesis is sharper than Grok's overproduction warning—it's not just supply glut, it's *directed* capital reallocation. MSOs flush with 280E relief will chase market share in high-margin states first (Florida, California), not deleverage. This creates a two-tier collapse: saturated markets crater while leaders consolidate. The margin gain from tax relief gets consumed by competitive intensity before interstate commerce ever materializes. This is the real earnings headwind.
"Even if Schedule III relief exists, the upside is not assured; interstate commerce, banking access, and cannibalization-driven price competition could erode 280E-margin gains."
Claude's assertion that Schedule III is 'already law' is a factual misstep that distracts from the real risk: even with any tax relief, MSOs face capital markets constraints and a looming cannibalization-driven price war in already saturated states. The true upside hinges on interstate commerce and banking access—both far from guaranteed—and the margin lift from 280E could be eroded by aggressive expansion. Therefore, near-term equity upside remains fragile.
The panel agrees that while Schedule III rescheduling provides immediate tax relief to cannabis operators, it falls short of full legalization and comes with significant risks. The key concern is that increased liquidity from tax relief could lead to aggressive expansion and overproduction, potentially offsetting the margin gains and driving down wholesale prices before interstate commerce opens.
Immediate tax relief for cannabis operators, potentially improving margins by 15-25%.
Cannibalization risk: aggressive expansion in saturated markets leading to a supply glut and price war.